XML 58 R51.htm IDEA: XBRL DOCUMENT v3.25.3
Segments - Schedule of Reportable Segment Loss (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Segment Reporting Information [Line Items]        
Chronic cough in IPF clinical trial expense $ 822 $ 4,592 $ 6,743 $ 11,116
Refractory chronic cough clinical trial expense 119 2,035 1,371 4,642
Clinical trial material 4,304 713 5,622 3,875
Other clinical trials and studies [1] 780 908 1,344 2,245
Other clinical development expenses [2] 1,549 1,217 4,827 2,969
Employee compensation (excluding stock compensation expense) 3,041 2,284 8,816 6,716
Stock-based compensation expense 1,243 822 3,835 2,671
Other segment items [3] 2,045 1,497 6,518 5,021
Interest income, net (2,101) (826) (4,633) (2,759)
Net loss $ 11,802 $ 13,242 $ 34,443 $ 36,496
[1] Includes expense related to the Company’s drug-drug interaction study, human abuse potential study, Phase 2 CANAL trial of Haduvio for the treatment of chronic cough in patients with IPF, and Phase 2b/3 PRISM trial of Haduvio for the treatment of prurigo nodularis.
[2] Includes expense related to general research and development activities, regulatory, medical affairs, and quality assurance.
[3] Includes general administrative expense, interest expense, net, other (expense) income, net and income tax benefit.